Product Code: ETC416997 | Publication Date: Oct 2022 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
USA Buprenorphine market currently, in 2023, has witnessed an HHI of 3594, Which has increased slightly as compared to the HHI of 2663 in 2017. The market is moving towards concentrated. Herfindahl index measures the competitiveness of exporting countries. The range lies from 0 to 10000, where a lower index number represents a larger number of players or exporting countries in the market while a large index number means fewer numbers of players or countries exporting in the market.
The United States Buprenorphine Market is experiencing significant growth due to the rising prevalence of opioid addiction and the increasing awareness of medication-assisted treatment. Buprenorphine, a medication used to treat opioid use disorder, is becoming a popular choice among healthcare providers and patients for its effectiveness in managing withdrawal symptoms and reducing cravings. The market is characterized by the presence of several key players offering various buprenorphine products, including sublingual tablets, sublingual films, and implants. The market is expected to continue growing as more healthcare providers incorporate buprenorphine into their treatment protocols and as government initiatives aim to expand access to medication-assisted treatment for opioid addiction across the country.
The US Buprenorphine Market is experiencing significant growth driven by the rising awareness and acceptance of medication-assisted treatment for opioid addiction. Increasing efforts to address the opioid epidemic have led to expanded access to buprenorphine, with more healthcare providers obtaining waivers to prescribe the drug. The market is also witnessing a shift towards long-acting buprenorphine formulations, offering extended-release options for improved patient adherence and outcomes. Additionally, telemedicine services for buprenorphine prescribing have gained traction, particularly during the COVID-19 pandemic, making treatment more accessible to underserved populations. Overall, the US Buprenorphine Market is poised for continued expansion as stakeholders focus on enhancing treatment access and outcomes for individuals with opioid use disorder.
In the US Buprenorphine market, challenges include limited access due to regulatory barriers such as the need for special licensing to prescribe the medication, stigma surrounding medication-assisted treatment for opioid addiction, and lack of comprehensive insurance coverage for buprenorphine therapy. Additionally, there is a shortage of healthcare providers who are trained and willing to prescribe buprenorphine, leading to disparities in access to treatment across different regions. The diversion and misuse of buprenorphine, particularly the sublingual film formulation, also pose challenges in ensuring its appropriate use for opioid dependence treatment. Addressing these challenges will require policy changes to improve access, increased education and training for healthcare providers, and efforts to reduce stigma and increase awareness about the effectiveness of buprenorphine therapy in combating the opioid epidemic.
The United States Buprenorphine Market presents promising investment opportunities due to the increasing prevalence of opioid addiction and the growing demand for medication-assisted treatments. With the opioid crisis continuing to be a major public health concern, the market for buprenorphine-based products is expected to expand significantly. Investors can explore opportunities in pharmaceutical companies developing innovative buprenorphine formulations, healthcare providers offering substance abuse treatment services, and telemedicine platforms providing virtual consultations for buprenorphine prescriptions. Additionally, investing in research and development for new buprenorphine delivery methods or combination therapies could prove to be lucrative in catering to the evolving needs of patients seeking effective opioid addiction treatment options.
In the United States, government policies related to the Buprenorphine market primarily focus on expanding access to this medication for the treatment of opioid use disorder. The Drug Addiction Treatment Act of 2000 allows qualified physicians to prescribe Buprenorphine outside of traditional opioid treatment programs, increasing availability. The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act of 2018 further expanded access by increasing the patient limit for Buprenorphine prescribers and encouraging its use in various healthcare settings. Additionally, the Comprehensive Addiction and Recovery Act (CARA) of 2016 aimed to improve coordination between federal agencies and support state-level initiatives to combat the opioid crisis, thereby impacting the Buprenorphine market through increased funding and resources for treatment programs.
The future outlook for the United States Buprenorphine Market looks promising, driven by the increasing prevalence of opioid use disorders and the growing awareness of the effectiveness of buprenorphine in treating addiction. The market is expected to experience steady growth due to the rising demand for medication-assisted treatment options and the expanded access to buprenorphine through initiatives aimed at reducing barriers to treatment. Additionally, advancements in drug delivery systems and formulations are likely to further enhance the market`s growth potential. With a supportive regulatory environment and a focus on addressing the opioid epidemic, the US Buprenorphine Market is anticipated to expand significantly in the coming years.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) Buprenorphine Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) Buprenorphine Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) Buprenorphine Market - Industry Life Cycle |
3.4 United States (US) Buprenorphine Market - Porter's Five Forces |
3.5 United States (US) Buprenorphine Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.6 United States (US) Buprenorphine Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.7 United States (US) Buprenorphine Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 United States (US) Buprenorphine Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 United States (US) Buprenorphine Market Trends |
6 United States (US) Buprenorphine Market, By Types |
6.1 United States (US) Buprenorphine Market, By Application |
6.1.1 Overview and Analysis |
6.1.2 United States (US) Buprenorphine Market Revenues & Volume, By Application, 2021-2031F |
6.1.3 United States (US) Buprenorphine Market Revenues & Volume, By Analgesic, 2021-2031F |
6.1.4 United States (US) Buprenorphine Market Revenues & Volume, By Opioid Antagonist, 2021-2031F |
6.2 United States (US) Buprenorphine Market, By Route of Administration |
6.2.1 Overview and Analysis |
6.2.2 United States (US) Buprenorphine Market Revenues & Volume, By Injectables, 2021-2031F |
6.2.3 United States (US) Buprenorphine Market Revenues & Volume, By Sublingual, 2021-2031F |
6.2.4 United States (US) Buprenorphine Market Revenues & Volume, By Transdermal Patches, 2021-2031F |
6.3 United States (US) Buprenorphine Market, By Distribution Channel |
6.3.1 Overview and Analysis |
6.3.2 United States (US) Buprenorphine Market Revenues & Volume, By Hospital Pharmacies, 2021-2031F |
6.3.3 United States (US) Buprenorphine Market Revenues & Volume, By Retail Pharmacies, 2021-2031F |
6.3.4 United States (US) Buprenorphine Market Revenues & Volume, By Online Pharmacies, 2021-2031F |
7 United States (US) Buprenorphine Market Import-Export Trade Statistics |
7.1 United States (US) Buprenorphine Market Export to Major Countries |
7.2 United States (US) Buprenorphine Market Imports from Major Countries |
8 United States (US) Buprenorphine Market Key Performance Indicators |
9 United States (US) Buprenorphine Market - Opportunity Assessment |
9.1 United States (US) Buprenorphine Market Opportunity Assessment, By Application, 2021 & 2031F |
9.2 United States (US) Buprenorphine Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.3 United States (US) Buprenorphine Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 United States (US) Buprenorphine Market - Competitive Landscape |
10.1 United States (US) Buprenorphine Market Revenue Share, By Companies, 2021 |
10.2 United States (US) Buprenorphine Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |